drugset / Trial / NCT01704872
ch14.18/CHO Bridging Study
Phase 1
Completed
16 enrolled
St. Anna Children's Cancer Research
Charite University, Berlin, Germany · collabIstituto Giannina Gaslini · collabSt. Anna Children's Hospital, Vienna · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, pharmacokinetic and activity profiles of the ch14.18 antibody produced in cells of hamster origin (ch14.18/CHO).
Timeline
- Start
- 2005-07
- Primary completion
- 2006-02
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dinutuximab | Monoclonal antibody | 10 mg/m2 | — |
| Subject | Dinutuximab | Monoclonal antibody | 20 mg/m2 | — |
| Subject | Dinutuximab | Monoclonal antibody | 30 mg/m2 | — |